CD138 (Syndecan-1) antibody | knockout validation | Biolegend 142502

This is a knockout-validated antibody summary, based on the publication "Syndecan 1 Is a Critical Mediator of Macropinocytosis in Pancreatic Cancer", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Rat monoclonal IgG2a, κ

Company: Biolegend

Antibody: CD138 (Syndecan-1)

Catalog number: 142502

Summary: Rat monoclonal IgG2a, κ against mouse mammary gland epithelial cell line NMuMG. Reacts with mouse syndecan-1 by flow cytometry, immunocytochemistry, immunohistochemistry (paraffin and frozen).

Validation Method

Immunohistochemistry

Sample

Sdc1−/− and Sdc1−/+ mice pancreatic tumors. Tissues were fixed in 10% formalin overnight, moved in 70% ethanol, and embedded in paraffin.

Figure

IHC staining (Sdc1 and Ki67) from pancreatic tumors of indicated genotypes (scale bar: 200 μm). Please see Figure 2h in the article [1].

Clone note

The same clone (281-2) is sold as BioLegend 142501, 142502, 142503, 142504, 142505, 142506, 142507, 142508, 142509, 142510, 142511, 142512, 142513, 142514, 142515, 142516, 142517, 142519, 142521, 142523, 142525, 142526, 142527, 142528, 142529, 142530, 142518, 142531, 142532, 142534; BD Biosciences 562610, 561070, 553714, 558626, 553712, 553713.

References
  1. Yao W, Rose J, Wang W, Seth S, Jiang H, Taguchi A, et al. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019;: pubmed publisher